Purpose To clarify the role of KAI1/CD82 in metastasis of nasopharyngeal carcinom and to evaluate the clinical efficacy of KAI1/CD82-expressing EPCs in the prevention of nasopharyngeal carcinoma.Method Umbilical vein-derived EPCs were infected with KAI1/CD82-expressing lenti-virus to get a KAI1/CD82-overexpressing EPC cell line (KAI1/CD82-EPCs).A xenograft mouse model of human nasopharyngeal carcinoma was established,and KAI1/CD82-EPCs were injected through the tail vein.The effect of the KAI1/CD82-EPCs on growth and metastasis of the xenograft was observed.Results Time required for tumor formation was 14.70 ± 3.81,15.05 ±3.85,14.20 ± 3.55 days respectively for the EPCs,EPCs-NC,and KAI1/CD82-EPCs groups,with no significant difference among the three groups (P =0.771).Weight of the xenograft was (1.388 ±0.204) g,(1.487 ±0.223) g,(1.485 ±0.234) g respectively for the EPCs,EPCs-NC,and KAI1/CD82-EPCs groups,with no significant difference (P =0.274).Rate of lung metastasis was 55％,45％ and 10％ for the EPCs,EPCs-NC,and KAI1/CD82-EPC groups,and the difference was significant (P =0.005).Number of metastatic lesions was 34.27 ± 5.35,38.44 ± 9.63,17.50 ± 3.54 for the three groups,and the difference was also significant (P =0.007).Immunohistochemistry indicated positive KAI1/CD82 expression in metastatic lesion of the KAI1/CD82-EPCs group,but no KAI1/CD82 expression in the EPCs group or EPCs-NC group.Conclusion KAI1/CD82-expressing EPCs inhibits lung metastasis of the xenograft mouse model of human nasopharyngeal carcinoma.

Objective To investigate the effect of progressive decompression on neurological function, long-term prognosis and complications in patients with severe craniocerebral injury undergoing modified large trauma craniotomy. Methods From January 2015 to January 2017, ninety patients with severe craniocerebral injury treated in Leizhou Shi People Hospital were selected and were randomly divided into the observation group (45 cases) and the control group (45 cases). The patients in the control group were treated with conventional decompression during the modified large bone flap decompression, and the patients in the observation group were treated with progressive decompression in the modified large bone flap decompression. The Glasgow Coma Scale (GCS) was used to evaluate the degree of damage before treatment and at 1d,3d,5 d,7d,14d, 30d after treatment,the intracranial pressure was monitored before treatment, at the surgical end, and at 1 d, 3 d, 5 d after surgery, the Glasgow′s prognostic score (GOS) was evaluated at 3 months after treatment. the neurobehavioral cognitive state checklist score ( NCSE) and the daily living ability score ( Barthel index ) were performed at 6 months after the operation, and the incidence of postoperative complications was recorded. Results The GCS scores of the observation group and the control group at 3d after treatment were respectively (5.70±0.82) points and (5.05±0.70) points], at 5d after treatment were (7.45±1.12) points and (5.81±0.82) points, at 7d after treatment were (9.38±0.52) points and (6.64±0.65) points, at 14 d after treatment were (10.31±0.79) points and (7.86±0.53) and at 30 d after treatment were (12.79±1.03) points and (10.13±1.31 points),which significantly higher than those before operation ((4.11±0.40), (4.15±0.42) points)(P＜0.05), and the scores of the observation group were significantly higher than those of the control group at each time interval ( P＜0.01). The intracranial pressure in the observation group and the control group were (26.64 + 3.02) and (29.79±2.57) mmHg respectively, (22.88±2.49) and (26.03±3.75) mmHg respectively at 1d after operation, (17.36±1.73) and (24.40±3.07) mmHg at 3d after operation.(14.20±1.18)mmHg and(21.06±2.64)mmHg at 5s after operation, All of them were significantly lower than that before operation (( 31.36 + 4.30) , ( 31.30 ±4.11) mmHg) (P＜0.05), and each time of the observation group was significantly lower than that of the control group (P＜0.01). The good recovery rate of the observation group was 22.22%(10/45), which was significantly higher than that of the control group (6.67%(3/45)). The difference between the two groups was statistically significant (χ2＝4.406, P＜0.05), the plant survival rates in the two groups were 4.44%(2/45) and 20%(9/45) respectively, the mortality rates were 13.33%(6/45) and 31.11%(14/45) respectively, and the two groups had statistical significance.(χ2＝5.050, 4.114, P＜0.05).The NCSE of the observation group and the control group were (69.24±8.42) points and (51.57±6.35) points at 6 months after operation, and the Barthel index was (76.97±5.57)points and (68.24±6.02)points respectively. The observation group was significantly higher than the control group ( t＝10.524, 8.713, P＜0.05). The total incidence of complications in the observation group was 24.44%( 11/45), which was significantly lower than that in the control group (60%) (27/45), and the difference was statistically significant (χ2＝11.660, P＜0.05). Conclusion It is more valuable to use progressive decompression in modified large bone flap decompression for severe craniocerebral injury, which can effectively protect the nerve function, reduce the incidence of complications in the perioperative period, and improve the effect of long－term prognosis.

Objective:To evaluate the efficacy and safety of apatinib in combination with chemoradiotherapy for head and neck squamous cell carcinoma (HNSCC).Methods:37 patients orally received apatinib at 250 mg/d during concurrent chemoradiotherapy until completion of radiotherapy, complete remission assessed by imaging examination, the onset of unacceptable toxicity or death. Baseline characteristics, objective response rates (ORR) and adverse events were assessed in all enrolled patients with complete baseline and safety data. Progression-free survival (PFS) and overall survival (OS) were calculated by Kaplan-Meier method. Prognostic factors were statistically identified using Cox regression models.Results:The ORR was 85%(95% CI: 72%-98%). The median PFS was 17.9 months and the 2-year OS rate was 62%(95% CI: 48%-80%). Ineffective short-term efficacy ( HR=0.035, 995% CI: 0.02-0.652, P=0.025) was an independent risk factor for poor OS. In addition, ineffective short-term efficacy ( HR=0.104, 95% CI: 0.017-0.633, P=0.014) and lymphocytopenia ( HR=17.539, 95% CI: 2.040-150.779, P=0.009) were independent risk factors for poor PFS. Common adverse events (>60%) included lymphocytopenia (76%), leukopenia (68%) and irradiation-induced mucosal injury (65%). The most common treatment-associated grade 3 adverse event was lymphopenia (49%). Conclusions:Apatinib combined with chemoradiotherapy yield significant anti-tumor activity for HNSCC with controllable toxicity. For patients with advanced HNSCC, short-term efficacy and lymphocytopenia may be potential predictors for clinical efficacy of apatinib combined with chemoradiotherapy.